L'Oréal inks buy three Valeant skin care brands with a $1.3bn deal
Consumer goods giant L’Oréal has paid $1.3bn to buy the CeraVe, AcneFree and AMBI skin care brands, which have a combined annualised revenue of roughly $168m. CeraVe is one of the fastest growing skin care brands in the US with average growth over the past two years exceeding 20%. CeraVe and AcneFree are both dermocosmetic brands, catering for sensitive and acne-prone skins, respectively. Meanwhile AMBI provides skin care products for multicultural consumers, with a focus on reducing the appearance of dark marks and skin discolouration. The three brands will be adding to the Active Cosmetics Division. CeraVe, AcneFree and AMBI are forecast to nearly double the revenue of L’Oréal’s Active Cosmetics Division, joining La Roche-Posay and Vichy
These brands will deepen L’Oréal'hips with health professionals and will strengthen our positions in North America in this key and fast growing market. Furthermore, we believe CeraVe has a great potential for international growth in the years to come.”
L'Oréal’s Active Cosmetics Division includes brands such as La Roche-Posay, Vichy and SkinCeuticals, developed with and endorsed by health professionals.
Valeant still owns a number of consumer health care brands including PeserVision and Ocuvite vitamins, and BioTrue lens care solutions.
The deal is due to close in the first quarter of this year.